-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On the evening of January 5, Dizhe Pharmaceuticals announced that the company has received the "Notice of Drug Clinical Trial Approval" approved and issued by the State Drug Administration for DZD8586, and agreed to approve the development of relapsed and refractory B cell non-Hodgkin drugs in China.
Clinical trials in Chikin's lymphoma
.
DZD8586 is an oral, highly selective, small molecule targeted drug that can penetrate the blood-brain barrier independently developed by the company.
It is a global innovative drug developed by the company based on the core technology platform of translational science for the treatment of tumors and other It has been approved by the State Food and Drug Administration to conduct clinical trials for relapsed and refractory B-cell non-Hodgkin lymphoma (NHL)
.
Preclinical studies have shown that DZD8586 has met the design expectations for all the drug indicators, has good safety and the ability to penetrate the blood-brain barrier, and can effectively inhibit the growth of B-cell non-Hodgkin's lymphoma cells